U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H17NO2
Molecular Weight 267.323
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of APOMORPHINE

SMILES

CN1CCc2cccc-3c2[C@@]1([H])Cc4ccc(c(c43)O)O

InChI

InChIKey=VMWNQDUVQKEIOC-CYBMUJFWSA-N
InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1

HIDE SMILES / InChI
Apomorphine (brand names: Apokyn, Ixense, Spontane, Uprima) is indicated for the acute, intermittent treatment of hypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson’s disease. Apomorphine has been studied as an adjunct to other medications. It is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action as a treatment for Parkinson’s disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the caudate-putamen in the brain.

CNS Activity

Curator's Comment:: Apomorphine quickly passes the nasal and intestinal mucosa as well as the blood-brain barrier (depending on the administration route)

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
APOKYN

Approved Use

APOKYN (apomorphine hydrochloride injection) is indicated for the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) in patients with advanced Parkinson's disease. APOKYN has been studied as an adjunct to other medications [see Clinical Studies (14)

Launch Date

1082419200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
47.5 pmol/mL
30 μg/kg bw single, subcutaneous
dose: 30 μg/kg bw
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
APOMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
41.7 pmol × h/mL
30 μg/kg bw single, subcutaneous
dose: 30 μg/kg bw
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
APOMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
33.6 min
30 μg/kg bw single, subcutaneous
dose: 30 μg/kg bw
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
APOMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4 mg single, respiratory
Highest studied dose
Dose: 4 mg
Route: respiratory
Route: single
Dose: 4 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
Other AEs: Somnolence, Dysgeusia...
Other AEs:
Somnolence (1 patient)
Dysgeusia (1 patient)
Dizziness (1 patient)
Orthostatic hypotension (1 patient)
Sources:
2.3 mg single, respiratory
Recommended
Dose: 2.3 mg
Route: respiratory
Route: single
Dose: 2.3 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
3 mg single, respiratory
Recommended
Dose: 3 mg
Route: respiratory
Route: single
Dose: 3 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
Other AEs: Somnolence, Yawning...
Other AEs:
Somnolence (1 patient)
Yawning (1 patient)
Flushing (1 patient)
Sources:
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Disc. AE: Cognitive impairment, Skin reaction...
AEs leading to
discontinuation/dose reduction:
Cognitive impairment (16 patients)
Skin reaction (14 patients)
Posture abnormal (12 patients)
Psychosis (11 patient)
Anxiety/depression (11 patient)
Hypotension (3 patients)
Gastrointestinal disorder (NOS) (1 patient)
Cardiovascular disorder (1 patient)
Weight loss (1 patient)
Excessive daytime sleepiness (1 patient)
Sources:
4 mg 1 times / day multiple, subcutaneous
Highest studied dose
Dose: 4 mg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 65.21 years
Health Status: unhealthy
Age Group: 65.21 years
Sex: M+F
Sources:
Disc. AE: Nausea and vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea and vomiting (187 patients)
Sources:
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Hallucination...
AEs leading to
discontinuation/dose reduction:
Hallucination (1%)
Sources:
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (3%)
Vomiting (2%)
Sources:
35 mg 1 times / day steady, sublingual
Recommended
Dose: 35 mg, 1 times / day
Route: sublingual
Route: steady
Dose: 35 mg, 1 times / day
Sources:
unhealthy, mean 62.9 years
Health Status: unhealthy
Age Group: mean 62.9 years
Sex: M+F
Sources:
Disc. AE: Respiratory tract signs and symptoms...
AEs leading to
discontinuation/dose reduction:
Respiratory tract signs and symptoms (9 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 1 patient
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
Dysgeusia 1 patient
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
Orthostatic hypotension 1 patient
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
Somnolence 1 patient
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
Flushing 1 patient
3 mg single, respiratory
Recommended
Dose: 3 mg
Route: respiratory
Route: single
Dose: 3 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
Somnolence 1 patient
3 mg single, respiratory
Recommended
Dose: 3 mg
Route: respiratory
Route: single
Dose: 3 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
Yawning 1 patient
3 mg single, respiratory
Recommended
Dose: 3 mg
Route: respiratory
Route: single
Dose: 3 mg
Sources:
unhealthy, 30 - 90 years
Health Status: unhealthy
Age Group: 30 - 90 years
Sex: unknown
Sources:
Cardiovascular disorder 1 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Excessive daytime sleepiness 1 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Gastrointestinal disorder (NOS) 1 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Weight loss 1 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Anxiety/depression 11 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Psychosis 11 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Posture abnormal 12 patients
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Skin reaction 14 patients
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Cognitive impairment 16 patients
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Hypotension 3 patients
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 44 - 87 years
Health Status: unhealthy
Age Group: 44 - 87 years
Sex: M+F
Sources:
Nausea and vomiting 187 patients
Disc. AE
4 mg 1 times / day multiple, subcutaneous
Highest studied dose
Dose: 4 mg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 65.21 years
Health Status: unhealthy
Age Group: 65.21 years
Sex: M+F
Sources:
Hallucination 1%
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Vomiting 2%
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nausea 3%
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Respiratory tract signs and symptoms 9 patients
Disc. AE
35 mg 1 times / day steady, sublingual
Recommended
Dose: 35 mg, 1 times / day
Route: sublingual
Route: steady
Dose: 35 mg, 1 times / day
Sources:
unhealthy, mean 62.9 years
Health Status: unhealthy
Age Group: mean 62.9 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak [Inhibition 50 uM]
weak [Inhibition 50 uM]
weak [Inhibition 50 uM]
weak [Inhibition 50 uM]
yes [IC50 50 uM]
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Involvement of GABAergic neurotransmission in the neurobiology of the apomorphine-induced aggressive behavior paradigm, a model of psychotic behavior in rats.
2000 Oct
The Posturo-Locomotion-Manual Test. A simple method for the characterization of neurological movement disturbances.
2001
Dopamine agonists.
2001
A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.
2001
Compulsive checking behavior of quinpirole-sensitized rats as an animal model of Obsessive-Compulsive Disorder(OCD): form and control.
2001
Intrapallidal dopamine restores motor deficits induced by 6-hydroxydopamine in the rat.
2001
Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study.
2001
Acute trazodone and quipazine treatment attenuates apomorphine-induced aggressive behaviour in male rats without major impact on emotional behaviour or monoamine content post mortem.
2001 Apr
Inhibition of baclofen on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity.
2001 Apr
The effects of apomorphine and haloperidol on memory consolidation in the day-old chick.
2001 Apr
Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation.
2001 Apr
Resolution of stroke deficits following contralateral grafts of conditionally immortal neuroepithelial stem cells.
2001 Apr
Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
2001 Apr
A nitric oxide-dopamine link pathway in organum vasculosum laminae terminalis of rat brain exerts control over blood pressure.
2001 Apr
Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo.
2001 Apr 1
Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage.
2001 Apr 13
Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration.
2001 Apr 15
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.
2001 Apr 27
Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice.
2001 Apr 27
NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats.
2001 Apr 6
Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats.
2001 Feb
Key issues from the clinical trials of apomorphine SL.
2001 Feb
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
2001 Feb
Comparison of the effects of infant handling, isolation, and nonhandling on acoustic startle, prepulse inhibition, locomotion, and HPA activity in the adult rat.
2001 Feb
Microencapsulated bovine chromaffin cell xenografts into hemiparkinsonian rats: a drug-induced rotational behavior and histological changes analysis.
2001 Feb
The role of neurochemical mechanisms of ventromedial hypothalamus in various models of anxiety in rats.
2001 Jan
Clinical and electrophysiological effects of apomorphine in Parkinson's disease patients are not paralleled by amino acid release changes: a microdialysis study.
2001 Jan-Mar
Erectile dysfunction.
2001 Jun
Startle and sensorimotor gating in rats lacking CCK-A receptors.
2001 Jun
Dopamine attenuates prefrontal cortical suppression of sensory inputs to the basolateral amygdala of rats.
2001 Jun 1
Entopeduncular lesions facilitate and thalamic lesions depress spontaneous and drug-evoked motor behavior in the hemiparkinsonian rat.
2001 Jun 1
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
2001 Jun 15
Corticosterone selectively attenuates 8-OH-DPAT-mediated hypothermia in mice.
2001 Mar
Reproductive experience modulates dopamine-related behavioral responses.
2001 Mar
Increased sensitivity of dopamine systems following reproductive experience in rats.
2001 Mar
Stimulus properties of 7-OH-DPAT versus auto- and postsynaptic receptor-specific doses of quinpirole.
2001 Mar
Differential effects of 7-OH-DPAT on the development of behavioral sensitization to apomorphine and cocaine.
2001 Mar
Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence.
2001 Mar
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
2001 Mar
Potent, hydroxyl radical-scavenging effect of apomorphine with iron and dopamine perfusion in rat striatum.
2001 Mar 30
Oral drug therapy for erectile dysfunction.
2001 May
Pharmacology of erectile function and dysfunction.
2001 May
Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?
2001 May
The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
2001 May
Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus.
2001 May
Interaction between D2 dopaminergic and glutamatergic excitatory influences on lower urinary tract function in normal and cerebral-infarcted rats.
2001 May
Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice.
2001 May
Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach.
2001 May
Intrasubthalamic injection of 6-hydroxydopamine induces changes in the firing rate and pattern of subthalamic nucleus neurons in the rat.
2001 May
Additive effect of clonidine and fluoxetine on apomorphine-induced aggressive behavior in adult male Wistar rats.
2001 May-Jun
Patents

Sample Use Guides

The recommended starting dose of is 0.2 mL (2 mg). Titrate on the basis of effectiveness and tolerance, up to a maximum recommended dose of 0.6 mL (6 mg)
Route of Administration: Other
In Vitro Use Guide
Apomorphine at concentrations of higher than 2 x 10(-5) M dramatically reduced the growth-stimulatory effect of retinal pigment epithelium (RPE) cells on the scleral chondrocytes, whereas the inhibitory effect of apomorphine on the proliferation of scleral chondrocytes without RPE cells was very little
Name Type Language
APOMORPHINE
HSDB   MI   VANDF   WHO-DD  
Common Name English
APOMORPHINUM
HPUS  
Common Name English
APOMORPHINE [HSDB]
Common Name English
APOMORPHINE [VANDF]
Common Name English
VR-040
Code English
APL-130277
Code English
VR040
Code English
4H-DIBENZO(DE,G)QUINOLINE-10,11-DIOL, 5,6,6A,7-TETRAHYDRO-6-METHYL-, (R)-
Common Name English
6A.BETA.-APORPHINE-10,11-DIOL
Common Name English
APOMORPHINUM [HPUS]
Common Name English
APOMORPHINE [WHO-DD]
Common Name English
APOMORPHINE [MI]
Common Name English
(6AR)-5,6,6A,7-TETRAHYDRO-6-METHYL-4H-DIBENZO(DE,G)QUINOLINE-10,11-DIOL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
WHO-ATC G04BE07
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
WHO-VATC QG04BE07
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
NDF-RT N0000175580
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
NCI_THESAURUS C38149
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
LIVERTOX 60
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
EU-Orphan Drug EU/3/01/072
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
FDA ORPHAN DRUG 89295
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
WHO-ATC N04BC07
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
NDF-RT N0000000117
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
FDA ORPHAN DRUG 107997
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
WHO-VATC QN04BC07
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
Code System Code Type Description
DRUG BANK
DB00714
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
MESH
D001058
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
PUBCHEM
6005
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
EPA CompTox
58-00-4
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
EVMPD
SUB12923MIG
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
ChEMBL
CHEMBL53
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
IUPHAR
33
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-360-0
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
CAS
58-00-4
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
MERCK INDEX
M2003
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C61639
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
FDA UNII
N21FAR7B4S
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
LACTMED
Apomorphine
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
HSDB
3289
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
DRUG CENTRAL
228
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
RXCUI
1043
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
APOMORPHINE
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY